Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rh Blood Group01:19

Rh Blood Group

1.4K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.4K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.0K
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.2K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.2K
Cross-reactivity00:42

Cross-reactivity

31.0K
Overview
31.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.

Open forum infectious diseases·2026
Same author

Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial.

European journal of preventive cardiology·2026
Same author

Respiratory syncytial virus vaccination and risk of respiratory and cardiorespiratory hospitalization in adults with chronic kidney disease: a prespecified analysis of the DAN-RSV trial.

European journal of preventive cardiology·2026
Same author

Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021-2022.

Pathogens (Basel, Switzerland)·2026
Same author

Vaccination Strategies Against Respiratory Pathogens in the Adult Population: A Narrative Review.

Vaccines·2026
Same author

Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Jun 21, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K

Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.

Charles Nuttens1, Juliette Moyersoen2, Daniel Curcio3

  • 1Pfizer Vaccines, Paris, France.

Infectious Diseases and Therapy
|July 6, 2024
PubMed
Summary

Respiratory Syncytial Virus (RSV) subgroups A and B cause severe disease, with no clear evidence of differing clinical severity. Public health interventions should target both RSV A and RSV B to effectively prevent illness.

Keywords:
Clinical severityEpidemiologyMonoclonal antibodiesRSV subgroupsRespiratory syncytial virusVaccines

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Related Experiment Videos

Last Updated: Jun 21, 2025

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

10.8K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

15.6K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

7.9K

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Respiratory Syncytial Virus (RSV) exists in two major subgroups, A and B.
  • Understanding their differences is crucial for developing effective prevention and public health strategies.

Purpose of the Study:

  • To describe structural, epidemiological, and genomic differences between RSV A and B.
  • To investigate associated immune responses and clinical severity variations.

Main Methods:

  • A comprehensive literature review was conducted using PubMed and Google Scholar from 1985 to 2023.
  • Snowballing techniques were employed to identify additional relevant publications.

Main Results:

  • RSV A and B differ in their G glycoprotein and surface-exposed regions of the prefusion F glycoprotein.
  • While both subgroups circulate annually, evidence for differential clinical severity remains inconclusive, with some studies suggesting a tendency for higher severity with RSV A.
  • Genomic diversity has decreased, with ON and BA lineages dominating since 2014, and no post-2014 studies report differing severity.
  • Some antigenic differences in the F glycoprotein exist, particularly in RSV B.
  • Preliminary data suggest faster waning of efficacy for RSV B compared to RSV A in certain vaccines.

Conclusions:

  • RSV A and B significantly contribute to the global RSV burden and cause severe disease.
  • Current evidence does not support differences in clinical severity between the subgroups.
  • Public health interventions must target both RSV A and B for maximum impact.
  • Ongoing monitoring is necessary to assess the impact of waning immunity on subgroup-specific vaccine efficacy.